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Background: Psychological conditions affect pain responses in the human anterior cingulate cortex (ACC)
according to brain imaging analysis. The rodent prefrontal cortex (PFC) including cingulate areas is also related to
the affective dimension of pain. We previously reported PFC nociceptive responses inhibited by inputs from the
amygdala, such as with dopamine (DA) D2 receptor (D2R) blockers, to show decreased effect on amygdala
projections. In this study, we examined whether direct projections from the ventral tegmental area (VTA) to the PFC
affect nociceptive responses in the PFC.
Results: High frequency stimulation (HFS, 50 Hz, 30 s) delivered to the VTA produced long-lasting suppression (LLS)
of nociceptive responses in the rat PFC including cingulate and prelimbic areas. Nociceptive responses evoked by
mechanical pressure stimulation (2 s duration at 500 g constant force) applied to the tails of urethane-anesthetized
rats were recorded using extracellular unit recording methods in the PFC. HFS delivered to the VTA, which has
been reported to increase DA concentrations in the PFC, significantly suppressed nociceptive responses. The LLS of
nociceptive responses persisted for about 30 minutes and recovered to the control level within 60 min after HFS.
We also demonstrated local microinjection of a selective D2 agonist of DA receptors to induce LLS of mechanical
nociceptive responses, while a D2 but not a D1 antagonist impaired the LLS evoked by HFS. In contrast, DA
depletion by a 6-hydroxydopamine injection or a low concentration of DA induced by a κ-opiate receptor agonist
injected into the VTA had minimal effect on nociceptive responses in the PFC.
Conclusion: HFS delivered to VTA inhibited nociceptive responses for a long period in PFC. DA D2R activation
mediated by local D2 agonist injection also induced LLS of mechanical nociceptive responses. The mesocortical DA
system may modify PFC nociceptive responses via D2 activity.
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Psychological conditions like attention [1] and hypnotic
effects [2] exert powerful influences on human pain sen-
sations. The anterior cingulate cortex (ACC) has crucial
roles in conscious perception of pain but not the sensory
discriminative aspect of pain [3]. Noxious stimulation
applied to peripheral tissues evoked nociceptive re-
sponses in rabbit and rodent cingulate and prelimbic
areas [4,5], lesions of which impaired place avoidance
test responses while pain behavior on the formalin test* Correspondence: blackcat@research.twmu.ac.jp
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University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
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reproduction in any medium, provided the orwas normal [6]. The human ACC and the rodent pre-
frontal cortex (PFC) receiving inputs from the amygdala
are involved in emotional processing [7]. In our previous
study [8], nociceptive responses of the PFC were
inhibited by inputs from the amygdala. We also found
that a dopamine (DA) D2 receptor (D2R) blocker im-
paired the inhibition induced by amygdala stimulation.
Direct dopaminergic projections from the ventral teg-
mental area (VTA) to the PFC are responsible for modu-
latory effects on nociceptive responses [9], suggesting
that the mesocortical DA system modulates pain re-
sponses in the PFC.
Recent studies have explored how DA modulates pain
perception [10]. Systemic administration of DA antagonistsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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toms of pain in Parkinson disease (PD) imply that DA levels
in the brain affect pain sensations. In clinical reports on
PD, patients frequently complain of neuropathic or central
pain before motor disorders [12-14]. These clinical reports
indicate that the brain DA level modifies pain sensations. In
animal studies, microinjections of DA into the ACC re-
duced autotomy scores in a sciatic neurotomy model [15].
Behavioral in vivo studies of pain have demonstrated that
DA depletion induces significant changes in thresholds for
noxious stimuli [16,17]. Six-hydroxydopamine (6-OHDA)
lesions in the VTA induced hyperalgesia in acute and
chronic pain models [18]. We determined whether
lower DA concentration changes in the VTA induced by
6-OHDA lesions alter nociceptive responses in the PFC.
We also examined effects of a κ-opiate receptor agonist
injected into VTA on nociceptive responses. Dopaminergic
projections from VTA have two main target areas, PFC
and the nucleus accumbens. A κ-opiate receptor agonist
injected into VTA inhibited only DA neurons projecting to
PFC and reduced DA level in PFC [19].
The rodent PFC receives DA projections from the
VTA. The present study demonstrated VTA-PFC projec-
tions to directly affect nociceptive responses recorded in
the PFC. VTA projections terminated at synapses within
the soma, dendritic shafts, and spines of pyramidal cells
in layers II to V of the PFC [20,21], while nociceptive in-
formation was transmitted through the medial pain
pathways from the periphery to the PFC [5,22]. The cru-
cial roles of DA in PFC function were discussed in the
review by Seamans [23]. The mesocortical DA pathways
from the VTA have modifying effects on cognition [24]
in the PFC. The VTA-PFC pathways may affect activities
of the medial pain pathways, of which the PFC is the
center. We analyzed the effects of dopaminergic inputs
from the VTA to the prelimbic and cingulate areas on
nociceptive responses in the PFC. We also clarified
which of the DA receptor subtypes is related to the
modulatory effects on nociceptive responses in the PFC.
Results
Mechanical noxious stimulation induced nociceptive
responses in the PFC
Mechanical noxious stimulation induced excitatory re-
sponses in PFC neurons, which persisted during and
frequently after stimulation. Two types of nociceptive re-
sponses, a wide dynamic range type and a specific high
threshold (SHT) type, were recorded [5]. In this study,
we used SHT neurons to monitor the response to nox-
ious stimulation. The spontaneous background dis-
charges of neurons, which usually showed the spindle
bursts characteristic urethane anesthesia, continued for
more than two hours, if the anesthetic level was
maintained like we had previously reported [5,8]. Weadministered additional urethane when typical spindle
bursts disappeared. Electrocorticography (ECoG) also
showed typical high amplitude slow waves and was
changed to low amplitude fast waves by mechanical
stimulation (Figure 1B). Anesthetic levels were also
detected with ECoG patterns. The nociceptive responses
were recorded without adaptation, if mechanical stimu-
lation was applied every 90 s.
HFS delivered to the VTA decreased nociceptive
responses in the PFC
High frequency stimulation (HFS, 50 Hz, 30 s) delivered
to the VTA impaired PFC nociceptive responses evoked
by mechanical stimulation applied to the rat tail
(11 units/9 rats) (Figure 1B). Durations of nociceptive
responses were 3.00 ± 0.46 s pre-HFS, and 0.82 ± 0.33 s
(36.9 ± 14.5% of pre-HFS) at 10 min (p<0.01), 1.05 ±
0.29 s (40.4 ± 12.7%) at 30 min (p<0.01) and 2.55 ± 0.60
s (91.0 ± 19.3%) at 60 min post-HFS (Figure 1C). Fre-
quencies of discharge were 5.43 ± 1.00 pre-HFS, and
2.06 ± 0.78 (38.8 ± 12.3% of pre-HFS) at 10 min
(p<0.01), 2.71 ± 1.01 (51.4 ± 16.8%) at 30 min and
4.34 ± 1.03 (93.3 ± 25.1%) at 60 min post-HFS
(Figure 1D). Long-lasting suppression (LLS) of nocicep-
tive responses appeared within 10 min and persisted for
30 min after HFS. Nociceptive responses recovered to
pre-HFS levels in 60 min. HFS delivered to the VTA
clearly inhibited nociceptive responses in the rat PFC.
D2R antagonist blocked the depression of nociceptive
responses
A D2R antagonist, sulpiride, which had no effect on con-
trol nociceptive responses, significantly blocked the inhibi-
tory effects of HFS (9 units/8 rats). Durations of pain
responses were 2.43 ± 0.46 s pre-microinjection and
2.69 ± 0.67 s post-microinjection. There was no significant
difference in nociceptive responses or background ECoG
between the two phases (pre & post D2R antagonist injec-
tion) (Figure 2B). After HFS had been delivered to the
VTA, the durations of nociceptive responses were 2.28 ±
0.45 s (85.0 ± 16.4% of pre-HFS) at 10 min, 2.36 ± 0.62 s
(94.8 ± 26.8%) at 30 min and 2.56 ± 0.41 s (103.7 ± 26.6%)
at 60 min post-HFS (Figure 2C). Frequencies of discharge
were 4.37 ± 1.00 s pre-HFS, post-microinjection, and
4.54 ± 1.64 (87.8 ± 24.1% of pre-HFS) at 10 min, 4.64 ±
1.30 (99.1 ± 21.4%) at 30 min and 4.43 ± 1.50 (95.0 ±
21.1%) at 60 min post-HFS (Figure 2D). In the sulpiride-
treated group, the durations and frequencies of pain
responses showed no statistically significant differences.
D1R antagonist had no effect on nociceptive responses in
the PFC
A D1 receptor (D1R) antagonist, SCH23390, had no
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Figure 1 HFS delivered to the VTA suppressed nociceptive responses recorded in the PFC. A: Time course of procedure is presented. Pre:
Pre-HFS. B: The top trace represents ECoG. The second trace is multiple unit discharges. The bottom trace represents a pressure curve.
Nociceptive responses were depressed by HFS delivered to the VTA at 10min. At 60 min after HFS, nociceptive responses recovered to the
pre-HFS control level. C, D: Inhibitory effects of VTA on nociceptive responses induced by HFS delivered to the VTA. Mean changes in the
duration (C) and frequency (D) of responses are presented. **p<0.01, Error bars represent S.E. n=11.
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microinjection and 1.97 ± 0.25 s post-microinjection.
There was no significant difference in nociceptive re-
sponses or background ECoG between the two phases
(pre & post D1R antagonist injection) (Figure 3B).
After HFS had been delivered to the VTA, the dura-
tions of nociceptive responses were 0.75 ± 0.31 s
(37.0 ± 14.6% of pre-HFS) at 10 min (p<0.01), 1.38 ±
0.35 s (70.0 ± 18.4%) at 30 min and 2.13 ± 0.70 s
(98.3 ± 23.2%) at 60 min post-HFS (Figure 3C). Fre-
quencies of discharge were 3.49 ± 0.57 pre-HFS,
post-microinjection, and 0.88 ± 0.30 (37.1 ± 17.8% of
pre-HFS) at 10 min (p<0.01), 1.78 ± 0.59 (64.2 ±
24.8%) at 30 min and 2.66 ± 0.61 (90.9 ± 25.0%) at
60 min post-HFS (Figure 3D).D2R agonist decreased nociceptive responses in PFC
A D2R agonist, quinpirole, decreased nociceptive re-
sponses in the PFC (9 units/5 rats) (Figure 4B).
Durations of pain responses were 1.54 ± 0.20 s pre-
microinjection, and 0.44 ± 0.13 s (31.4 ± 10.9% of pre-
HFS) at 10 min (p<0.01), 0.94 ± 0.28 s (68.6 ± 22.0%) at
30 min and 1.44 ± 0.24 s (104.8 ± 25.4%) at 60 min
post-microinjection (Figure 4C). Frequencies of dis-
charge were 6.09 ± 1.31 pre-microinjection, and 2.43 ±
0.72 (44.0 ± 11.5% of pre-HFS) at 10 min (p<0.01),
4.16 ± 0.94 (81.1 ± 15.4%) at 30 min and 3.67 ± 0.97
(90.2 ± 23.4%) at 60 min post-microinjection
(Figure 4D). LLS of nociceptive responses appeared
within 10 min after microinjection. Nociceptive re-

































































Figure 2 Microinjection of a D2R antagonist modified the depression of nociceptive responses induced by HFS. A: Time course of
procedure is presented. Pre1: Pre-HFS (before sulpiride microinjection). Pre2: Pre-HFS (after sulpiride microinjection). B: The top trace represents
ECoG. The second trace is multiple unit discharges evoked by mechanical stimulation. The third trace represents single unit responses selected by
cluster analysis from multiple units in the top line. The bottom trace represents a pressure curve. The D2R antagonist, sulpiride, impaired effects of
HFS delivered to the VTA. C, D: At 10 and 30 min after HFS, a D2R antagonist blocked the depression of nociceptive responses induced by HFS to
the VTA to a statistically significant extent. Mean changes in the duration (C) and frequency (D) of responses are presented. Error bars represent
S.E. n=9.
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nociceptive responses in the PFC.
κ-opiate receptor agonist microinjection into the VTA
A κ-opiate receptor agonist, U50488, microinjected into
the VTA had no effect on nociceptive responses or back-
ground ECoG in the PFC (9 units/7 rats) (Figure 5A(a)).
Durations of pain responses were 1.94 ± 0.44 s pre-
microinjection, and 1.67 ± 0.46 s (103.5 ± 22.0% of pre-
microinjection) at 10 min, 1.83 ± 0.51 s (98.7 ± 23.7%)
at 30 min and 1.89 ± 0.48 s (114.4 ± 38.4%) at 60 min
post-microinjection (Figure 5A(b)). Frequencies of dis-
charge were 3.99 ± 0.43 pre-microinjection, and 3.84 ±
1.63 (85.7 ± 29.7% of pre-microinjection) at 10 min, 3.71 ±0.77 (97.4 ± 25.2%) at 30 min and 4.32 ± 1.35 (99.1 ±
28.3%) at 60 min post-microinjection (Figure 5A(c)).DA depletion had no effect on nociceptive responses in
the PFC
DA depletion was established by apomorphine tests
three weeks after 6-OHDA injection into the medial
forebrain bundle (MFB). In apomorphine test-positive
animals, background ECoG showed low voltage fast
waves, as described in a previous report [25]. However,
nociceptive responses were normally evoked by mechan-
ical stimulation delivered to the tail. There was no differ-
ence in mean nociceptive responses between the control
A
recording




























































Figure 3 Microinjection of D1R antagonist had no effect on the inhibitory effects of HFS. A: Time course of procedure is presented. Pre1:
Pre-HFS (before SCH23390 microinjection). Pre2: Pre-HFS (after SCH23390 microinjection). B: The top trace represents ECoG. The second trace is
multiple unit discharges evoked by mechanical stimulation. The third trace represents single unit responses selected by cluster analysis from
multi-units of the top trace. The bottom trace represents a pressure curve. Nociceptive responses were depressed by HFS delivered to the VTA at
10min. At 60 min after HFS, nociceptive responses showed recovery to the pre-HFS control level. C, D: Mean changes in the duration (C) and
frequency (D) of responses are presented. **p<0.01, Error bars represent S.E. n=8.
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3.93 ± 0.68 s, respectively) (Figure 5B).
Discussion
Our study examined whether the mesocortical DA
system directly affects nociceptive responses in the
PFC. HFS delivered to the VTA inhibited nociceptive
responses recorded in the PFC. Basically, the DA con-
centration in the PFC, which receives direct inputs
from the VTA [20,21], is tonically maintained by
activities of dopaminergic neurons in the VTA. HFS
delivered to the VTA [26] and activation of VTA neu-
rons by N-methyl-D-aspartate (NMDA) [27] increase
the extracellular DA concentration, thereby producinginhibitory effects on PFC neurons [28]. Higher DA
concentrations induced by HFS may produce inhib-
ition of nociceptive responses in the PFC. The inhib-
ition, which was induced by a HFS of a moderate
intensity, persisted for 60 min. In PFC slice studies,
bath application of DA strongly modulated long-term
depression of glutamatergic synapses [29]. Our previ-
ous in vivo study [8] indicated that DA modulated
LLS induced by glutamate receptor activation. Burst
stimulation of VTA increased DA release in PFC,
which induced plasticity of PFC neurons [30]. DA
release by HFS delivered to VTA may induce plastic
changes in glutamatergic synapses to receive nocicep-





















































Figure 4 Microinjection of D2R agonist suppressed nociceptive responses recorded in the PFC. A: Time course of procedure is presented.
Pre: Pre-quinpirole microinjection. B: The top trace is multiple unit discharges evoked by mechanical stimulation. The second trace represents
single unit responses selected by cluster analysis from multi-units. The bottom trace represents a pressure curve. Nociceptive responses were
depressed by D2R agonist, quinpirole, microinjection at 10 min. C, D: Mean changes in the duration (C) and frequency (D) of responses are
presented. **p<0.01, Error bars represent S.E. n=9.
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a decrease in the DA concentration induced by κ-opiate
application [19] had no effect on nociceptive responses
in the PFC. DA depletion by 6-OHDA increased the low
amplitude and high frequency components in back-
ground ECoG, as reported previously [25]. Decreased
tonic DA release suppressed D2-mediated activities
followed by augmentation of PFC neuron activities [32].
These reports indicate that a low level of DA affects
spontaneous activities of PFC neurons, but effects on
evoked responses remain unclear. Our results and those
of a previous report [8] demonstrated a low DA concen-
tration in the PFC to impair plastic changes but not nor-
mal nociceptive responses.
In the rodent PFC, local application of DA reportedly
induced spike activities, while a D2R antagonist impaired
suppression of spontaneous discharges [28,33,34]. Our
results from HFS to the VTA and local injection of a
D2R agonist indicate D2R activation to be responsible
for the LLS of nociceptive responses induced by HFS of
the VTA. A D1R antagonist, however, had minimal
effects on nociceptive responses, as reported by Godbout
[28]. DA D1R and D2R are found on both pre- and post-
synaptic pyramidal neurons in the PFC [35-37]. D1R
activating adenylate cyclase through interactions with G-
proteins (Gs) [38] enhanced the NMDA current [39],
which induced long-term potentiation (LTP) in the PFC
[40]. A question is why HFS did not evoke excitatoryeffects via D1Rs activities. More D1Rs are expressed on
gamma-aminobutyric acid (GABA) neurons than on
pyramidal cells in the PFC [41], suggesting that D1R ac-
tivities evoked by HFS did not consistently induce exci-
tatory responses. Another possibility is that DA D1R
produces an inverted-U shaped response, indicating a
higher dose to be associated with somewhat lower per-
formance [42,43]. The DA concentrations induced by
HFS of the VTA may evoke DA D2- but not DA D1-
mediated activities in PFC neurons.
The PFC receives numerous projections from sev-
eral areas involved in complex higher brain func-
tions. The medial pain pathways extend from the
periphery to the PFC [5,22] and direct projections
from the VTA terminate in the PFC. Both inputs
converged in the same areas (Additional file 1)
where unit discharges were recorded in this study.
Projections from the amygdala and hippocampus also
terminate in the PFC and thereby change pain re-
sponses [8,44]. These areas are related to emotion
and memory, suggesting that the PFC unifies affec-
tional information and pain. According to human
brain imaging analyses, the strength of conscious
pain, which is related to psychological condition, re-
flects activities of the PFC [45]. DA modified synap-
tic plasticity [8,46] and prolonged DA-mediated
modulation biases the long-term processing dynam-






































































Figure 5 Microinjection of κ-opiate receptor agonist and DA depletion had no effect on nociceptive responses in PFC. A: (a) The top
trace represents ECoG. The second trace is multiple unit discharges evoked by mechanical stimulation. The third trace represents single unit
responses selected by cluster analysis from multi-units. The bottom trace represents a pressure curve. Mean changes in the duration (b) and
frequency (c) of responses are presented. Error bars represent S.E. n=9. B: Nociceptive discharges were recorded in the PFC of the side ipsilateral
to 6-OHDA injection. There was no difference in mean nociceptive responses between the control (n= 8) and 6-OHDA groups (n=10). Error bars
represent S.E.
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Mechanical noxious stimulation applied peripherally
evoked nociceptive discharges in the PFC. HFS delivered
to the VTA inhibited persistently nociceptive responses
recorded in the PFC. This long lasting inhibition was de-
creased by a DA D2R antagonist. In addition, a D2R
agonist alone produced inhibition of nociceptive re-
sponses. The DA system (VTA-PFC projections) exerts
modulatory effects on pain responses recorded in the




Adult male Wistar rats (270-350 g; Sankyo Laboratory
Co., Tokyo, Japan) were used in all experiments. The
rats were housed under controlled temperature (25°C)
and humidity (40-50%) conditions with a 12-h light/darkcycle, and had free access to food and water. Experi-
ments conformed to guidelines issued by the National
Institutes of Health for Laboratory Animals and all pro-
cedures were approved by the Animal Experimental
Committee of Tokyo Women’s Medical University.
Efforts were made to minimize the number of animals
used and their suffering. All rats were anesthetized with
a single injection of urethane (1.5 g/kg, i.p.) and
mounted in a stereotaxic instrument (Narishige, Tokyo,
Japan) for the acute experiments.
Mechanical stimulation
Mechanical pressure was applied to the tail (1.0-2.0 cm
distal to the body) employing a mechanical stimulator
(DPS-270; DIA Medical System Co., Tokyo, Japan),
using a probe with a circular contact area with a 1 mm-
in-diameter tip. Mechanical stimuli were delivered every
90 s at constant force with a feedback system. Stimulus
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(and decreasing) time to maximum force and a 2 s hold
time. The nociceptive stimulus intensity of 300 gf has
been shown to be adequate [47] to induce C-fiber medi-
ated activity in peripheral nerves [48]. These mechanical
stimulus conditions induced stabile nociceptive re-
sponses lasting more than two hours under the same
anesthetic levels. (For details, refer to our previous re-
ports [5,8]).Electrophysiological recording
Recording tungsten needle microelectrodes (impedance
8-12 MΩ; FHC, ME, USA) were stereotaxically posi-
tioned in the cingulate or prelimbic areas of the PFC.
Stereotactic coordinates of the PFC were 2.8-4.2 mm an-
terior and 0.3-0.8 mm lateral to the Bregma [49]. The
perpendicular depths of the recording sites were be-
tween 0.2 and 2.2 mm from the dorsal cortical surface
(Figure 6A(a)). The unit spikes were processed with a
multichannel amplifier (MEG-6100; Nihon Kohden Co.,
Tokyo, Japan; 0.08-3000 Hz) and an active filter (DV-04;
NF Electronic Instruments Co., Yokohama, Japan; 500-
3000 Hz), respectively. Through a memory oscilloscope
(VC-11; Nihon Kohden Co.), the data were fed into a
thermal array recorder (RTA-1100M; Nihon Kohden
Co.) for paper recording and a personal computer
(Vostro420; Dell, TX, USA) via an integrated system
(PowerLab/4SP; Mountain View, CA, USA) for record-
ing storage and later off-line analysis. The spontaneous
background discharge patterns and ECoG were recorded
through the same electrodes. Anesthetic levels and noci-
ceptive responses were determined with ECoG. We ad-
ministered additional urethane when typical spindle
bursts disappeared. ECoG changed from slow waves with
spindle bursts to low amplitude fast waves induced by
mechanical stimulation (Figure 1B).Local application of drugs
A cannula (0.18 mm inside diameter, Teflon) with
a stainless recording electrode (TF205-074, Unique
Medical Co., Tokyo, Japan) was stereotaxically positioned
in the left PFC or VTA. The cannula was connected by
polyethylene tubing (30 cm length) to a 25 μl syringe
(Hamilton, NV, USA). The drug was microinjected by
means of a syringe pump at a rate of 1 μl/min (55-1111;
Harvard Apparatus Co., MA, USA). All drugs were
dissolved in 0.9% saline. The following barrel concentra-
tions were used: 5 μM/5 μl sulpiride (D2R antagonist;
Sigma, St. Louis, MO, USA), 5 μM/5 μl quinpirole (D2R
agonist; Sigma), 100 nM/6 μl SCH23390 (D1R antagon-
ist; Sigma), 100 μM/5 μl U-50488 (κ-opiate receptor
agonist; Sigma). Sulpiride, SCH23390 and quinpirole
were locally injected into the PFC. A κ-opiate receptoragonist, U-50488, was injected into the VTA to decrease
DA concentrations [19].
HFS applied to the VTA
In these experiments, tungsten needle microelectrodes
(impedance 8-12 MΩ; FHC) were positioned in the
VTA. Stereotactic coordinates of the VTA were 4.5-5.5
mm posterior and 0.3-0.8 mm lateral to the Bregma.
The perpendicular depths of the recording sites were be-
tween 7.5 and 8.5 mm from the dorsal cortical surface
(Figure 6A(b)). Electrical HFS (50 Hz, 250 μA, 100μs
square pluses, for 30 s) was applied to the VTA to in-
crease DA concentrations in the PFC [50].
Depletion of DA
Rats were anesthetized with Nembutal (50 mg/kg i.p.).
Then, five μl of 6-OHDA HCl (2 mg in 1ml of saline
containing 0.1% ascorbic acid; Sigma) were injected into
the left MFB through a cannula with a microinjection
pump at a rate of 20 μl/hr, and the cannula was left in
place for 10 min after the completion of pumping.
Stereotactic coordinates of the MFB were 4.5 mm pos-
terior and 1.1 mm lateral to the Bregma. The perpen-
dicular depths of the recording sites were 8.2 mm from
the dorsal cortical surface. At the end of injection, the
cannula was removed and the skull skin was sutured.
We assessed motor disturbance 3 weeks after 6-OHDA
injection by circling behavior (LE 902/Rp Container;
Panlabs.I., Barcelona, Spain) with apomorphine (1 mg/kg
i.p.) administration. The same acute experimental proce-
dures as described above (Recording and stimulating
electrodes) were carried out after DA depletion had been
established. Nociceptive discharges were recorded in the
PFC of the side ipsilateral to 6-OHDA injection. Apo-
morphine induced rotational asymmetry was not ob-
served in the intact group (Pre-6-OHDA treatment)
serving as the control. Before the 6-OHDA injections,
we performed apomorphine tests (1 mg/kg i.p.) to avoid
spontaneous DA abnormalities.
Unit recording locations
The locations of units were marked with a positive elec-
tric current lesion (direct current, 100 μA for 15 s). At
the end of each experiment, the animals were perfused
with normal saline and 4% paraformaldehyde. After
overnight post-fixation, the brains were sectioned (50
μm) and stained with Cresyl Violet solution to examine
the recording sites under light microscopy.
Data analysis
A single unit spike was discriminated on the basis of the
height and width of each unit from a multi-unit record-
ing obtained (scatter plotting Figure 6B(b) left) and the
same single units were determined from clusterized
Bregma -4.80 mm
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Figure 6 Recording site and stimulus point locations and data analysis. A: (a) Recording sites in the PFC. All unit discharges are scattered
throughout the cingulate and prelimbic areas. Solid circles represent the recording sites. Drug injection and recording sites (solid triangles: D2R
antagonist, solid squares: D1R antagonist, and open triangles: D2R agonist). The numbers represent the distance from the Bregma. Cg1: cingulate
cortex area 1. PrL: prelimbic cortex. IL: infralimbic cortex. (b) Stimulus and drug injection sites in the VTA. Solid circles represent the locations to
which HFS was delivered. Open circles represent the locations at which the κ-opiate receptor agonist was injected. B: (a) The top trace is
multiple unit discharges. The second trace represents discriminated single units. The bottom trace represents a pressure curve. Nociceptive
stimulation activated discharges. (b) Cluster analysis of single units (red) with wave width and height on the left. Right side traces represent
waves on the left figure. Red units on the left have the same forms. (c) Responses are shown as a histogram with 1sec bin after single units were
discriminated. Vertical lines represent the stimulus starting point.
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Software LabChart 7.0 (AD Instruments Co., Tokyo,
Japan) was used for unit discharge analysis. The spike
histogram was analyzed using single spikes during a
22s period (10s before stimulation and 10s after
stimulation, Figure 6B(c)). Each bin of histograms
consists of spikes during a 1 s period. The durations
of responses exceeding double the mean spontaneousdischarges on the histogram were assessed as the
response durations (Figure 6B(c)). Significant differ-
ences in discharges evoked by mechanical stimuli
were assessed with the nonparametric paired-test
(Wilcoxon) to compare pre- and post- stimulation
values. Data are expressed as means ± standard errors
(S.E.). A probability level of <0.05 was considered
significant.
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Additional file 1: Convergence of VTA and medial pain pathways in
the superficial layer of the PFC.
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